AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01462812
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT01571856
Drug: Zinc Sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: zinc sulfate solution, contains 20 mg. per 5 mL. dosage 2.5 mL. per day.
Trial: NCT01533935
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo matching tiotropium + olodaterol
Trial: NCT03071224
Drug: [18F] MNI-946
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will undergo PET imaging using \[18F\]MNI-946, a PET radioligand for imaging tau.
Trial: NCT03136705
Drug: Nicotinamide
RxNorm normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinamide tablet
Trial: NCT02146079
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule.
Trial: NCT02855411
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, twice daily (BID) for 12 weeks, capsule
Trial: NCT03587038
Drug: OKN 007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg OKN-007/mL in a phosphate buffer
Trial: NCT03965988
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01936285
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00080314
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0 mg, Once daily, 8 weeks.
Trial: NCT03741699
Drug: Pre-treatment with rLH (Luveris 75 IU),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with 150 IU/day rLH (Luveris 75 IU), administered subcutaneously for 4 consecutive days prior to COS (Controlled ovarian stimulation)
Trial: NCT01194557
Drug: Lumartem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presumptive treatment of malaria/fever
Trial: NCT00471952
Drug: Maxalt 10mg MLT plus Caffeine 75mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One migraine attack will be treated
Trial: NCT00471952
Drug: Placebo + Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One migraine attack will be treated with double placebo
Trial: NCT02538237
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the mouthwash(ibuprofen 2% or placebo) Subgingival Irrigation of mouthwash with an insulin syringe 0.5 ml were rinsed.
Trial: NCT02538237
Drug: Ibuprofen 2% mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00398541
Drug: losartan potassium (+) hydrochlorothiazide
RxNorm normalized name: hydrochlorothiazide / losartan potassium Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan potassium (+) hydrochlorothiazide combination will be titrated upwards according to the following scheme: losartan potassium 50/hydrochlorothiazide 12.5 then losartan potassium 100/hydrochlorothiazide 12.5 then losartan potassium 100/hydrochlorothiazide 25
Trial: NCT04123561
Drug: TLC599
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLC599 is a proprietary (Bioseizer) lipid formulation containing DSP (active ingredient)
Trial: NCT00653835
Drug: Ezetimibe + Simvastatin
RxNorm normalized name: ezetimibe / simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets: ezetimibe 10 mg + simvastatin 20 mg once daily for 6 weeks
Trial: NCT00653835
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral tablets: simvastatin 20 mg + ezetimibe placebo once daily for 6 weeks
Trial: NCT00193440
Drug: CVP
RxNorm normalized name: CVP Manometer
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03237832
Drug: ARN-6039
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending doses per Cohort
Trial: NCT02053272
Drug: GWP42004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The total dose administered within any 24-hour interval will be two capsules (typically 12 hours apart).
Trial: NCT02053272
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The total dose administered within any 24-hour interval will be two capsules (typically 12 hours apart).
Trial: NCT03632681
Drug: Intranasal Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal placebo manufactured to mimic smell of insulin
Trial: NCT04181567
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03521167
Drug: Tylenol Pill
RxNorm normalized name: Tylenol Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-operatively use. 1000 mg PO up to 1 hour before OR time Reduce to 650 mg PO if \<70kg Don't use if h/o liver disease or anticipated liver injury (right heart failure, pulmonary hypertension, etc leading to systemic venous congestion)
Trial: NCT04314167
Drug: Lowering cholesterol concentrations by PCSK-9 inhibitor
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive the PCSK9-inhibitor Evolocumab as part of routine clinical management within the indication of this drug.
Trial: NCT02891031
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg twice daily after meal for 6 weeks
Trial: NCT03023982
Drug: Opioids
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard pain control with opioids
Trial: NCT00468975
Drug: PF-610,355
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02191423
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered pre-fMRI assessment
Trial: NCT00532948
Drug: capecitabine [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg/m2 po bid (starting dose)
Trial: NCT02032537
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical water containing emollient (placebo) will be applied by the patient on the affected skin area whenever the pruritus starts including night time. The frequency of application will be regulated by individual patients and increased according to pruritus severity. The data on efficacy, duration of effect and frequency of application will be collected.during the study.
Trial: NCT02345252
Drug: FTC/RPV/TDF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally once daily
Trial: NCT02345252
Drug: FTC/RPV/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200/25/300 mg FDC tablets administered orally once daily
Trial: NCT02345252
Drug: FTC/RPV/TAF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally once daily
Trial: NCT02515864
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02812433
Drug: Ora-Blend
RxNorm normalized name: Ora-Blend Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ora-Blend, 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
Trial: NCT03982771
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: -Cyclophosphamide: (oral) 300mg/m2 on Day 1, 8, 15, 22 every month for 9 months;
Trial: NCT01184417
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 m l saline
Trial: NCT02413125
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Most nasal irrigations use normal saline (0.9% sodium chloride), which approximates the physiological concentration of plasma in the blood. The saline solution is used to flush the nose of mucous and allergens.
Trial: NCT01702363
Drug: GSK573719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK573719 inhalation powder inhaled orally once daily for 52 weeks.
Trial: NCT03252496
Drug: Intrathecal Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 15 μg will be administered in the subarachnoid space
Trial: NCT03252496
Drug: 250 mL Crystalloid over 60 minutes
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After 60 minutes of intrathecal injection, Ringer acetate 250 mL will be administered over 60 minutes
Trial: NCT03252496
Drug: Intravenous Syntocinon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately after delivery, syntocinon 10 IU will be added to the running crystalloid solution
Trial: NCT02195791
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral) 1 tab once daily for 7 days
Trial: NCT01293032
Drug: Aromatase Inhibition Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo hormonal therapy
Trial: NCT00321984
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
Trial: NCT00911027
Drug: Contrast-enhanced ultrasound guided biopsy
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One to two bolus (each 2.4mL) of SonoVue per patient in the optimization part~One to four bolus (each 2.4mL) of SonoVue per patient in the main part
Trial: NCT02203331
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
Trial: NCT02777073
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of generic placebo
Trial: NCT01197144
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous, every other week for 4 weeks
Trial: NCT00658372
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, oral, placebo, BID, 8 weeks with 2 week taper
Trial: NCT05118958
Drug: KVD824 Prototype 1 modified-release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg modified-release tablet
Trial: NCT05118958
Drug: KVD824 Immediate-Release Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg immediate-release capsule
Trial: NCT05118958
Drug: Placebo to KVD824 Prototype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to 300 mg KVD824 Prototype 1 modified-release tablet
Trial: NCT05118958
Drug: KVD824 Prototype 3 modified-release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg modified-release tablet
Trial: NCT00740779
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00450203
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dose banded as based on patient BSA. Oral dose given twice a day during each 21 day cycle of chemotherapy (6 cycles in total)
Trial: NCT02344069
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 0.9% as a injection
Trial: NCT05029596
Drug: Heparin Group
RxNorm normalized name: Heparin group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All lumens of PICC line will be flushed w/ Heparin Flush every 8 hours. PICC line will be flushed with 10cc Normal Saline followed by 3cc Heparin Flush after administration of medication, blood products, or blood draws.
Trial: NCT02714673
Drug: anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anticoagulation refers to any long term effective anticoagulation including antivitamin K, direct oral anticoagulants. Aspirin, clopidogrel are not included
Trial: NCT01996735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04023695
Drug: Corticosteroid with lidocaine with epinephrine
RxNorm normalized name: epinephrine / lidocaine Cartridge [Xylocaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trigger finger injection
Trial: NCT04095286
Drug: AMB new formulation (1 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMB tablets will be available at a unit dose strength of 1 mg. Participants will orally administer 5 tablets of 1 mg unit dose.
Trial: NCT04095286
Drug: Reference AMB (5 mg)
RxNorm normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AMB reference tablet will be available as film-coated tablet at unit dose strength of 5 mg. Participants will orally administer 1 tablet of 5 mg unit dose
Trial: NCT02216331
Drug: TMC207
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a two group, 2 period study design with both groups in the first period receiving TMC207 alone, followed by one group in the second period receiving TMC207 in the presence of dosing with rifapentine and the other group receiving TMC207 in the presence of dosing with rifampicin. All treatments details specified under Arms description.
Trial: NCT03870711
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile water 4 puffs
Trial: NCT01477190
Drug: Spinal analgesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: isobaric bupivacaine 0.5% 10 mg together with preservative-free morphine was injected. The dose of morphine was based on patient's age, with 200 μg in patients aged ≤ 75 years and 150 μg in patients aged \> 75 years.
Trial: NCT00313807
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Saline Infusion
Trial: NCT02819310
Drug: BLI400 Laxative
RxNorm normalized name: LAXATIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral laxative
Trial: NCT04243083
Drug: TLL018 tablet, placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral QD
Trial: NCT00080873
Drug: Traumeel S
RxNorm normalized name: Traumeel S Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02388360
Drug: topical prostaglandin analogs
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04688346
Drug: HemeRX epinephrine pellets
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Racemic Epinephrine Pellet
Trial: NCT03276936
Drug: FMX103 1.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMX103 1.5% minocycline foam
Trial: NCT03041116
Drug: Fosmetpantotenate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dosing
Trial: NCT03041116
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dosing
Trial: NCT01598857
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03333057
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution (0.9% sodium chloride solution)
Trial: NCT02029794
Drug: 3-5% acetic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00137852
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given twice daily 3 days prior to radiation and up until one week prior to surgery. It will then be started again once the participant is released from the hospital following surgery for 26 weeks.
Trial: NCT04022811
Drug: 0.1% bromfenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the patients received the use of the Ponacore 3 days before and 7 days after the operation. Local eye drops, 2 times a day.
Trial: NCT02037802
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02849990
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04397406
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patients will receive 13 ml of 0.125% levobupivacaine and 25μg fentanyl diluted in 2 ml saline.
Trial: NCT04218916
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo capsules once, three times a day
Trial: NCT01902082
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01072097
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 6 months
Trial: NCT02676076
Drug: CHF 5993 100/6/12.5 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02676076
Drug: CHF 1535 100/6 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00863785
Drug: Corticoids plus N Acetyl Cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/d prednisolone N Acetyl Cysteine infusion 150mg/kg in 30 minutes then 50 mg/kg in 4 h then 100mg/kg in 16 h and finally 100mg/d2 to d5
Trial: NCT02544906
Drug: dexmedetomedine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of dexmedetomedine to prevent emergence agitation in liver transplanta recipients
Trial: NCT02116465
Drug: Levodopa Carbidopa immediate release tablets
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT01775891
Drug: other class IC antiarrhythmic drug
RxNorm normalized name: Antiarrhythmics, class Ic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other class IC antiarrhythmic drug that they had been taking before catheter ablation will be administrated.(flecainide 100mg bid PO or propafenone 225mg tid) Antiarrhythmic drug will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
Trial: NCT03497325
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 55 participant unergoing prelabor primary CS will receive intramyometrial injection of normal saline after closure of uterine incision
Trial: NCT00389896
Drug: MK0733 / Duration of Treatment: 18 Weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00389896
Drug: Comparator: placebo (unspecified) / Duration of Treatment: 18 Weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03791125
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets containing no salvianolic acid A will be given to healthy subjects.
Trial: NCT00142480
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally for 14 consecutive days (days 1-14) followed by a week of no capecitabine then another week of 14 consecutive days (days 21-28).
Trial: NCT01883440
Drug: Saline+glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo arm
Trial: NCT03736538
Drug: Placebo gas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gas given at 50% nitrogen \[inert\]/50% oxygen.
Trial: NCT00972244
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily, 12 weeks
Trial: NCT00335504
Drug: sulindac
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00335504
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02216253
Drug: L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract tablet twice a day 7 days before and after surgery
Trial: NCT01986569
Drug: [18F]fluoroestradiol (FES)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]FES PET/CT will be performed 90 min (± 10 min) after administration of \[18F\]FES. Patients will undergo core needle biopsy or surgery within 15 days after \[18F\]FES PET; or patients will undergo core needle biopsy within 30 days before \[18F\]FES PET. Experienced pathologists will determine metastatic/recurrent disease, and tumor histology including IHC. Patient will undergo surgery, radiation therapy or systemic therapy according to the results of staging workup, histology and biomarkers.
Trial: NCT02930798
Drug: BAY987516
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z46-116)
Trial: NCT03554005
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and continue acetaminophen 500 to 1000 mg after administration every 4 to 6 hours as needed. The total daily dose of acetaminophen should not exceed 3000 mg.
Trial: NCT02542605
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered once on day 1 of Part B of the study by intravenous infusion.
Trial: NCT02542605
Drug: PACAP-38 Challenge Agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intravenous infusion during Part A of the study for dose selection for Part B.~Administered by intravenous infusion on day 8 in Part B as a challenge agent to induce a migraine-like attack.